32 Multiple Myeloma Clinical Trials in Birmingham, AL (2026)

Q: How do I join a clinical trial in Birmingham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you.

Recruiting Multiple Myeloma Studies in Birmingham

NCT05591066Recruiting

The Patient and Family Centered I-PASS LISTEN Study: Language, Inclusion, Safety, and Teamwork for Equity Now

In 2014, a team of parents, nurses, and physicians created Patient and Family Centered I-PASS (PFC I-PASS), a bundle of communication interventions to improve the quality of information exchange betwe...

Birmingham, ALNA14,400 participantsBoston Children's Hospital

View Study Details

NCT05556928Recruiting

Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry

The primary purpose of this protocol is to create a registry of older (≥50 years old) patients with Hematologic Malignancies. Our main objectives include: To understand the prevalence of frailty and g...

Birmingham, AL5,000 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04634552Recruiting

A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)....

Birmingham, ALPHASE2510 participantsJanssen Research & Development, LLC

View Study Details

NCT06615479Recruiting

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple My...

Birmingham, ALPHASE3440 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06581328Recruiting

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this stud...

Birmingham, ALPHASE4400 participantsTakeda

View Study Details

NCT06365060Recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is o...

Birmingham, AL400 participantsTufts Medical Center

View Study Details

NCT06158841Recruiting

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, in...

Birmingham, ALPHASE3380 participantsAbbVie

View Study Details

NCT03816345Recruiting

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, an...

Birmingham, ALPHASE1300 participantsNational Cancer Institute (NCI)

View Study Details

NCT05231629Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is mu...

Birmingham, ALPHASE2300 participantsUniversity of Alabama at Birmingham

View Study Details

NCT03937635Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenal...

Birmingham, ALPHASE3288 participantsECOG-ACRIN Cancer Research Group

View Study Details

NCT05372354Recruiting

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Mul...

Birmingham, ALPHASE1260 participantsBristol-Myers Squibb

View Study Details

NCT06858579Recruiting

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP)....

Birmingham, ALPHASE3256 participantsDianthus Therapeutics

View Study Details

NCT04973605Recruiting

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM)...

Birmingham, ALPHASE1246 participantsBeiGene

View Study Details

NCT06297226Recruiting

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma....

Birmingham, ALPHASE2230 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06121843Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants w...

Birmingham, ALPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Birmingham, ALPHASE1187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT05850234Recruiting

A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

This trial is a phase 1b/2, open-label, multicenter study of GC012F (AZD0120), a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple Myeloma....

Birmingham, ALPHASE1182 participantsAstraZeneca

View Study Details

NCT07116616Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM)....

Birmingham, ALPHASE1166 participantsModernaTX, Inc.

View Study Details

NCT07091630Recruiting

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or pl...

Birmingham, ALPHASE3160 participantsargenx

View Study Details

NCT07266441Recruiting

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells c...

Birmingham, ALPHASE2157 participantsJanssen Research & Development, LLC

View Study Details

NCT07113522Recruiting

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the saf...

Birmingham, ALPHASE2140 participantsMirador Therapeutics, Inc.

View Study Details

NCT06974786Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary ob...

Birmingham, ALPHASE2100 participantsSCRI Development Innovations, LLC

View Study Details

NCT06829238Recruiting

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. ...

Birmingham, ALPHASE4100 participantsUniversity of Alabama at Birmingham

View Study Details

NCT07221123Recruiting

Boosting Olfactory and Sensory Training Study (BOOST)

The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1. Determin...

Birmingham, ALPHASE280 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06988488Recruiting

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRM...

Birmingham, ALPHASE162 participantsCelgene

View Study Details

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to deter...

Birmingham, ALPHASE150 participantsCaribou Biosciences, Inc.

View Study Details

NCT06533098Recruiting

A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT)....

Birmingham, ALPHASE350 participantsJanssen Research & Development, LLC

View Study Details

NCT04991103Recruiting

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with...

Birmingham, ALPHASE240 participantsUniversity of Alabama at Birmingham

View Study Details

NCT04929236Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients...

Birmingham, ALPHASE330 participantsOctapharma

View Study Details

NCT05642884Recruiting

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

This is a pilot feasibility trial among older adults (≥60y) scheduled to undergo Autologous Stem Cell transplantation at UAB. Participants will be randomized into either a prehabilitation program or a...

Birmingham, ALNA30 participantsNoha Mohamed Sharafeldin

View Study Details

NCT07333261Recruiting

Study of BMS-986453 in Newly Diagnosed Multiple Myeloma

This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell trans...

Birmingham, ALPHASE125 participantsSusan Bal

View Study Details

NCT05193552Recruiting

Usage of Spirometry in Managing IgG Therapy in CVID With Airway Disease

Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published s...

Birmingham, ALPHASE422 participantsUniversity of Alabama at Birmingham

View Study Details

About Multiple Myeloma Clinical Trials in Birmingham

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 32 multiple myeloma clinical trials recruiting participants in Birmingham, AL. These studies are seeking a combined 25,178 participants. Research is being sponsored by Boston Children's Hospital, University of Alabama at Birmingham, Janssen Research & Development, LLC and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Birmingham — FAQ

Are there multiple myeloma clinical trials in Birmingham?

Yes, there are 32 multiple myeloma clinical trials currently recruiting in Birmingham, AL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 32 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 17, 2026 from ClinicalTrials.gov